| Literature DB >> 29930314 |
Shmuel Benenson1, Ran Nir-Paz2, Mordechai Golomb3, Carmela Schwartz2, Sharon Amit2, Allon E Moses2, Matan J Cohen2,4.
Abstract
Medical tourism has a potential of spreading multi-drug resistant bacteria (MDR). The Hadassah Medical Center serves as a referral center for global medical tourists and for Palestinian Authority residents. In order to assess whether patients of these groups are more likely to harbor MDR bacteria than local residents, we reviewed data from all patients admitted to our institution between 2009 and 2014. We compared MDR rates between countries of residency, controlling for gender, age, previous hospitalization and time from admission to MDR detection. Overall, among 111,577 patients with at least one microbiological specimen taken during hospitalization, there were 3,985 (3.5%) patients with at least one MDR-positive culture. Compared to Israeli patients, tourists and patients from the Palestinian Authority had increased rates of MDR positivity (OR, 95%CI): 2.3 (1.6 to 2.3) and 8.0 (6.3 to 10.1), respectively. Our data show that foreign patients seeking advanced medical care are more likely to carry MDR bacteria than the resident population. Strategies to minimize MDR spread, such as pre-admission screening or pre-emptive isolation should be considered in this population.Entities:
Mesh:
Year: 2018 PMID: 29930314 PMCID: PMC6013425 DOI: 10.1038/s41598-018-27908-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart of patient selection, exclusion and multi drug resistant (MDR) rates. The study period extended from July 1st 2009 to December 31st 2014. Only patients admitted at least once and from whom at least one microbiological specimen was obtained were included in the study. Patients were classified into three groups and in each, the rate of MDR bacteria was calculated twice, once excluding and once including carbapenem-resistant Pseudomonas aeruginosa (CR-PA) and extended-spectrum-beta-lactamase producing Enterobacteriaceae (ESBL-PE) (see text).
Patient characteristics (N = 111,577).
| Variable | N (%) | p-value | ||
|---|---|---|---|---|
| Residence | Israeli | Palestinian Authority | Foreign tourists | |
| Number of patients | 108,783 | 1653 | 1141 | |
| Female gender | 61,754 (57%) | 641 (39%) | 572 (50%) | <0.001 |
| Age group (years) | ||||
| Up to 18 | 31,488 (29) | 653 (40) | 162 (14) | <0.001 |
| 18 to 40 | 31,115 (29) | 465 (28) | 291 (26) | |
| 40 to 65 | 21,974 (20) | 401 (24) | 389 (34) | |
| 65 to 80 | 14,840 (14) | 108 (7) | 227 (20) | |
| above 80 | 9,366 (9) | 26 (2) | 72 (6) | |
| Previous 6 months admissions | ||||
| None | 61,872 (57) | 1,152 (70) | 867 (76) | <0.001 |
| One | 31,839 (29) | 267 (16.2) | 176 (15) | |
| More than one | 15,072 (14) | 234 (14) | 98 (9) | |
| ICU stay, previous 6 months | 4,661 (4.3) | 107 (6.5) | 37 (3.2) | <0.001 |
ICU, intensive care unit.
Multi drug resistant carriage rates.
| Variable | N (%) | p-value | |||
|---|---|---|---|---|---|
| Residence | Israeli | Palestinian Authority | Foreign tourists | Total | |
| Number of patients | 108,783 | 1,653 | 1,141 | 111,577 | |
| MDR positivity (overall) | 3,722 (3.4) | 201 (12.2) | 62 (5.4) | 3,985 (3.6) | <0.001 |
| MDR positivity according to time after hospital admission | |||||
| Up to 96 hours | 1,590 (1.5) | 96 (5.8) | 36 (3.2) | 1,722 (1.5) | <0.001 |
| 96 hours–1 week | 352 (0.3) | 16 (1.0) | 4 (0.4) | 372 (0.3) | |
| More than one week | 1,780 (1.6) | 89 (5.4) | 22 (1.9) | 1,891 (1.7) | |
| MDR-specific positivity rates | |||||
| CRE | 769 (0.7) | 31 (1.9) | 19 (1.7) | 819 (0.7) | <0.001 |
| VRE | 616 (0.6) | 25 (1.5) | 16 (1.4) | 657 (0.6) | <0.001 |
| MRSA | 1,205 (1.1) | 58 (3.5) | 13 (1.1) | 1,276 (1.1) | <0.001 |
| CR_ACIN | 770 (0.7) | 73 (4.4) | 17 (1.5) | 860 (0.8) | <0.001 |
| | 1,393 (1.3) | 56 (3.4) | 16 (1.4) | 1,465 (1.3) | <0.001 |
*C. difficile positivity rates among patients whose stool samples were tested: Israeli 15.7%, Palestinian 17.6%, foreign tourists 9.8%.
MDR, multi-drug resistant; CRE, carbapenemase-producing Enterobacteriaceae; VRE, vancomycin-resistant Enterococci; MRSA, methicillin-resistant Staphylococcus aureus; CR-ACIN, carbapenem-resistant Acinetobacter baumannii.
Figure 2Multi drug resistant (MDR) prevalence per age group and source population. Each panel depicts MDR prevalence per age group. Columns depict the cumulative MDR rate in each age group, per patient nationality. The color specifications depict the time from hospital admission to first identification of MDR bacteria. Palestinian patients were found to have the highest rates of MDR bacteria in all age groups. Among patients up to 40 years old, foreign tourists had higher MDR rates than Israeli patients. In the older age groups, MDR rates were lower among foreign tourists. In most age groups about half of MDR bacteria were identified in the first 96 hours after admission.
Regression models assessing the risk of multi-drug resistant bacteria positivity.
| Variable | Odds Ratio (95%CI) | |||||
|---|---|---|---|---|---|---|
| Bacteria | Any MDR bacteria* | CRE | VRE | MRSA | CR-ACIN |
|
| Female | 0.68 (0.63 to 0.74) | 0.65 (0.54 to 0.78) | 0.79 (0.65 to 0.96) | 0.6 (0.52 to 0.68) | 0.48 (0.41 to 0.56) | 0.8 (0.7 to 0.92) |
| Residence (reference: Israeli patients) | ||||||
| Palestinian | 8.0 (6.3 to 10.1) | 6.8 (3.8 to 12.1) | 7.3 (3.8 to 13.7) | 5.1 (3.4 to 7.6) | 13.5 (8.4 to 21.7) | 5.7 (3.8 to 8.5) |
| Foreign tourists | 2.3 (1.6 to 3.3) | 4.9 (2.4 to 10.1) | 2.5 (1.2 to 5.1) | 0.85 (0.45 to 1.65) | 2.7 (1.4 to 5.4) | 1.1 (0.7 to 1.9) |
| Age (reference: age up to 18) | ||||||
| 18 to 40 | 1.05 (0.9 to 1.2) | 1.9 (1.2 to 2.8) | 2.3 (1.5 to 3.6) | 0.8 (0.63 to 1.0) | 3.5 (2.5 to 5.1) | 0.9 (0.7 to 1.1) |
| 40 to 65 | 3.2 (2.8 to 3.6) | 7.6 (5.3 to 11.1) | 10.9 (7.2 to 16.4) | 2.1 (1.7 to 2.6) | 9.5 (6.7 to 13.3) | 3 (2.4 to 3.8) |
| 65 to 80 | 5.9 (5.2 to 6.7) | 19 (13.1 to 27.4) | 16.6 (11 to 25.2) | 4.0 (3.2 to 4.9) | 11.6 (8.3 to 16.4) | 6.4 (5.2 to 8) |
| above 80 | 9.1 (7.9 to 10.4) | 26 (17.8 to 38.1) | 18.2 (11.8 to 28.2) | 4.6 (3.7 to 5.8) | 15.8 (11 to 22.8) | 11.5 (9.3 to 14.5) |
MDR, multi-drug resistant; CRE, carbapenem resistant Enterobacteriaceae; VRE, vancomycin resistant Enterococci; CR-ACIN, carbapenem resistant Acinetobacter baumannii.
*The model was also controlled for hospitalization in the prior six months.